Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.61 USD | -1.48% | +1.64% | +60.83% |
05-15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
05-13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+60.83% | 1.76B | |
+19.33% | 125B | |
+13.95% | 108B | |
-3.53% | 24.57B | |
+2.71% | 22.82B | |
-9.95% | 18.19B | |
-41.48% | 16.54B | |
-12.62% | 16.5B | |
+0.99% | 13.39B | |
+21.79% | 11.1B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Transcript : Aeglea BioTherapeutics, Inc. - Special Call